<li>amiodarone<p>amiodarone increases levels of lidocaine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Higher doses of amiodarone (ie, 600 mg BID) were shown to significantly increase lidocaine levels.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>bosutinib increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>brexpiprazole<p>lidocaine will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor. <span><br><br></span>lidocaine will increase the level or effect of brexpiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP3A4 inhibitor PLUS a strong/moderate CYP2D6 inhibitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>cabozantinib<p>lidocaine will increase the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>cigarette smoking<p>cigarette smoking will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>ciprofloxacin will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Lidocaine plasma levels may be elevated, increasing the risk of toxicity. Monitor cardiac function and symptoms of toxicity.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of lidocaine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>darunavir<p>darunavir increases levels of lidocaine by decreasing metabolism. Use Caution/Monitor.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>disopyramide<p>disopyramide, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of arrhythmia, heart failure in predisposed pts.</p></li><li>eliglustat<p>eliglustat increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of lidocaine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>hawthorn<p>hawthorn increases effects of lidocaine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>hyaluronidase<p>hyaluronidase, lidocaine. Other (see comment). Use Caution/Monitor. 
Comment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>ivacaftor<p>lidocaine increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Reduce ivacaftor dose to 150 mg once daily when coadministered with moderate CYP3A4 inhibitors.</p></li><li>lomitapide<p>lomitapide increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>mefloquine<p>lidocaine will increase the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>mexiletine<p>mexiletine will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>modafinil<p>modafinil will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).<span><br><br></span>nadolol increases levels of lidocaine by decreasing elimination. Use Caution/Monitor. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of lidocaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>norfloxacin<p>norfloxacin will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of lidocaine by  decreasing metabolism. Modify Therapy/Monitor Closely. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when coadministered with Technivie.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of lidocaine by  decreasing metabolism. Modify Therapy/Monitor Closely. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when coadministered with Viekira Pak</p></li><li>palbociclib<p>lidocaine will increase the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>peginterferon alfa 2a<p>peginterferon alfa 2a will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).<span><br><br></span>pindolol increases levels of lidocaine by decreasing elimination. Use Caution/Monitor. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).</p></li><li>pipemidic acid<p>pipemidic acid will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>ponatinib<p>ponatinib increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>primidone<p>primidone will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>procainamide<p>lidocaine, procainamide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Either suppresses myocardial conduction by increasing electrical stimulation threshold of the ventricle and His-Purkinje fibers.</p></li><li>propranolol<p>propranolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).<span><br><br></span>propranolol increases levels of lidocaine by decreasing elimination. Use Caution/Monitor. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).</p></li><li>rifampin<p>rifampin will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>ruxolitinib<p>lidocaine will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>sevelamer<p>sevelamer decreases levels of lidocaine by increasing elimination. Use Caution/Monitor.</p></li><li>smoking<p>smoking will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>sonidegib<p>lidocaine will increase the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of sonidegib with moderate CYP3A4 inhibitors. If a moderate CYP3A inhibitor must be used, administer the moderate CYP3A inhibitor for &lt;14 days and monitor closely for adverse reactions, particularly musculoskeletal adverse reactions.</p></li><li>suvorexant<p>lidocaine will increase the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease suvorexant starting dose to 5 mg HS if coadministered with moderate CYP3A4 inhibitors</p></li><li>tacrine<p>tacrine will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>tamsulosin<p>lidocaine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.<span><br><br></span>lidocaine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>telaprevir<p>telaprevir will increase the level or effect of lidocaine by  Other (see comment). Use Caution/Monitor. Coadministration with telaprevir has the potential to produce serious and/or life-threatening adverse events and has not been studied. Caution is warranted and therapeutic concentration monitoring is recommended during concurrent use.</p></li><li>timolol<p>timolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol).<span><br><br></span>timolol increases levels of lidocaine by decreasing elimination. Use Caution/Monitor. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol).</p></li><li>tobacco use<p>tobacco use will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>tofacitinib<p>lidocaine increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.</p></li><li>verapamil<p>verapamil will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>zileuton<p>zileuton will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li>